Literature DB >> 19238391

PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences.

Bernd Klaeser1, Michel D Mueller, Ralph A Schmid, Carlos Guevara, Thomas Krause, Jakub Wiskirchen.   

Abstract

Positron emission tomography-computed tomography (PET-CT) has gained widespread acceptance as a staging investigation in the diagnostic workup of malignant tumours and may be used to visualize metabolic changes before the evolution of morphological changes. To make histology of PET findings without distinctive structural changes available for treatment decisions, we developed a protocol for multimodal image-guided interventions using an integrated PET-CT machine. We report our first experience in 12 patients admitted for staging and restaging of breast cancer, non-small cell lung cancer, cervical cancer, soft tissue sarcoma, and osteosarcoma. Patients were repositioned according to the findings in PET-CT and intervention was planned based on a subsequent single-bed PET-CT acquisition of the region concerned. The needle was introduced under CT guidance in a step-by-step technique and correct needle position in the centre of the FDG avid lesion was assured by repetition of a single-bed PET-CT acquisition before sampling. The metabolically active part of lesions was accurately targeted in all patients and representative samples were obtained in 92%. No major adverse effects occurred. We conclude that PET-CT guidance for interventions is feasible and may be promising to optimize the diagnostic yield of CT-guided interventions and to make metabolically active lesions without morphological correlate accessible to percutaneous interventions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19238391     DOI: 10.1007/s00330-009-1338-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  16 in total

1.  Percutaneous CT-guided biopsy of osseous lesion of the spine in patients with known or suspected malignancy.

Authors:  Eric Lis; Mark H Bilsky; Leszek Pisinski; Patrick Boland; John H Healey; Bernie O'malley; George Krol
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

2.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.

Authors:  Gerald Antoch; Nina Saoudi; Hilmar Kuehl; Gerlinde Dahmen; Stefan P Mueller; Thomas Beyer; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

3.  Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.

Authors:  S Mahner; S Schirrmacher; W Brenner; L Jenicke; C R Habermann; N Avril; J Dose-Schwarz
Journal:  Ann Oncol       Date:  2008-03-19       Impact factor: 32.976

Review 4.  Molecular imaging techniques in body imaging.

Authors:  Daniel J A Margolis; John M Hoffman; Robert J Herfkens; R Brooke Jeffrey; Andrew Quon; Sanjiv S Gambhir
Journal:  Radiology       Date:  2007-11       Impact factor: 11.105

5.  CT-guided interventions in orthopedics.

Authors:  Klaus Huch; Götz Röderer; Benno Ulmar; Heiko Reichel
Journal:  Arch Orthop Trauma Surg       Date:  2007-07-26       Impact factor: 3.067

6.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

7.  Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.

Authors:  Elena Piperkova; Barbara Raphael; Mustafa E Altinyay; Ivan Castellon; Richard Libes; Nick Sandella; Sherif Heiba; Hussein Abdel-Dayem
Journal:  Clin Nucl Med       Date:  2007-06       Impact factor: 7.794

8.  Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Authors:  D-S Shin; O-J Shon; S-J Byun; J-H Choi; K-A Chun; I-H Cho
Journal:  Skeletal Radiol       Date:  2008-02-29       Impact factor: 2.199

9.  Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer.

Authors:  B Klaeser; O Wiederkehr; D Koeberle; A Mueller; B Bubeck; B Thuerlimann
Journal:  Ann Oncol       Date:  2007-08       Impact factor: 32.976

10.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.

Authors:  Thomas Völker; Timm Denecke; Ingo Steffen; Daniel Misch; Stefan Schönberger; Michail Plotkin; Juri Ruf; Christian Furth; Brigitte Stöver; Hubertus Hautzel; Günter Henze; Holger Amthauer
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

View more
  14 in total

1.  PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact.

Authors:  Bernd Klaeser; Jakub Wiskirchen; Jan Wartenberg; Thilo Weitzel; Ralph A Schmid; Michel D Mueller; Thomas Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-03       Impact factor: 9.236

2.  Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer.

Authors:  Francois H Cornelis; Jeremy C Durack; Neeta Pandit-Taskar; Gary A Ulaner; Jason S Lewis; Michael J Morris; Stephen B Solomon
Journal:  J Nucl Med       Date:  2017-08-17       Impact factor: 10.057

3.  Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.

Authors:  Francois H Cornelis; Jeremy C Durack; Michael J Morris; Howard I Scher; Stephen B Solomon
Journal:  Clin Nucl Med       Date:  2017-12       Impact factor: 7.794

4.  Real-time intraprocedural 18F-FDG PET/CT-guided biopsy using automated robopsy arm (ARA) in the diagnostic evaluation of thoracic lesions with prior inconclusive biopsy results: initial experience from a tertiary health care centre.

Authors:  Renjith Kalathoorakathu Radhakrishnan; Bhagwant Rai Mittal; Arun Kumar Reddy Gorla; Rajender Kumar Basher; Ashwani Sood; Amanjit Bal; Naveen Kalra; Niranjan Khandelwal; Navneet Singh; Digambar Behera
Journal:  Br J Radiol       Date:  2017-10-27       Impact factor: 3.039

5.  FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies.

Authors:  M K Werner; P Aschoff; M Reimold; C Pfannenberg
Journal:  Br J Radiol       Date:  2011-03       Impact factor: 3.039

6.  Cone-beam computed tomography fusion and navigation for real-time positron emission tomography-guided biopsies and ablations: a feasibility study.

Authors:  Nadine Abi-Jaoudeh; Peter Mielekamp; Niels Noordhoek; Aradhana M Venkatesan; Corina Millo; Alessandro Radaelli; Bart Carelsen; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2012-04-10       Impact factor: 3.464

7.  Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities.

Authors:  F Cornelis; M Silk; H Schoder; H Takaki; J C Durack; J P Erinjeri; C T Sofocleous; R H Siegelbaum; M Maybody; S B Solomon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-09       Impact factor: 9.236

8.  Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.

Authors:  Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Chadwick L Wright; Edward W Martin
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

9.  Positron emission tomography/computed tomography for bone tumors (Review).

Authors:  Aikeremujiang Muheremu; Xiaohui Niu
Journal:  Oncol Lett       Date:  2014-11-21       Impact factor: 2.967

10.  18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.

Authors:  Stephen P Povoski; Douglas A Murrey; Sabrina M Smith; Edward W Martin; Nathan C Hall
Journal:  BMC Cancer       Date:  2014-06-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.